

Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study: Erratum

In the article, “Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study”^[1] which published in Volume 100, Issue 44 of *Medicine*, the values in the OR column of Table 2 were rounded. The correct table appears below and have been corrected in the published article.

Insert Table 2

Reference

- [1] Tanaka R, Sato J, Ishikawa H. Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study. *Medicine*. 100;44:e27565.

| rs1799971 Alt allele freq: 0.494 A > G ORRM1 | | | | | | | | | | | | | | | | | | | | |
|--|------------|------------|---------|-------------|-------|-----------|------------|------|-------------|--------|-----------|------------|-----|-------------|-------|------------|------------|-----|-------------|-------|
| Allele | A/A | | A/G+G/G | | G/G | | A/A+A/G | | OR | 95% CI | P | C/C | T/T | | | | | | | |
| | n=22 | n=66 | n=66 | n=67 | n=21 | n=67 | n=56 | n=32 | | | | | | | | | | | | |
| Somnolence | 6 (27.3%) | 13 (19.7%) | 1.5 | 0.5 to 4.7 | .55* | 0 (0.0%) | 19 (28.4%) | 0 | 0 to 0.6 | .005* | 1 (20.0%) | 18 (21.7%) | 0.9 | 0.1 to 8.6 | 1.00* | 10 (17.9%) | 9 (28.1%) | 0.6 | 0.2 to 1.6 | .29* |
| Nausea | 1 (4.5%) | 13 (19.7%) | 0.2 | 0.02 to 1.6 | .17* | 5 (23.8%) | 9 (13.4%) | 2.0 | 0.6 to 6.9 | .31* | 0 (0.0%) | 14 (16.9%) | 0 | 0 to 6.0 | 1.00* | 23 (21.4%) | 2 (6.3%) | 4.1 | 0.9 to 19.6 | .07* |
| Constipation | 10 (45.5%) | 24 (36.4%) | 1.5 | 0.6 to 3.9 | .46* | 9 (42.9%) | 25 (37.3%) | 1.3 | 0.5 to 3.4 | .49* | 1 (20.0%) | 33 (39.8%) | 0.4 | 0.04 to 3.5 | .64* | 23 (41.1%) | 11 (34.4%) | 1.3 | 0.5 to 3.3 | .65* |
| Delirium | 1 (4.5%) | 9 (13.6%) | 0.3 | 0.04 to 2.5 | .44* | 3 (14.2%) | 7 (10.4%) | 1.4 | 0.3 to 6.1 | .70* | 0 (0.0%) | 10 (12.0%) | 0 | 0 to 9.2 | 1.00* | 6 (10.7%) | 4 (12.5%) | 0.8 | 0.2 to 3.2 | 1.00* |
| Urinary retention | 0 (0.0%) | 3 (4.5%) | 0 | 0 to 7.6 | 1.00* | 2 (9.5%) | 1 (1.5%) | 7.0 | 0.6 to 80.8 | .14* | 0 (0.0%) | 3 (3.6%) | 0 | 0 to 46.4 | 1.00* | 2 (3.6%) | 1 (3.1%) | 1.2 | 0.1 to 13.2 | 1.00* |
| Pruritus | 4 (18.1%) | 8 (12.1%) | 1.6 | 0.5 to 6.0 | .49* | 2 (9.5%) | 10 (14.9%) | 0.6 | 0.1 to 3.00 | .72* | 0 (0.0%) | 12 (14.5%) | 0 | 0 to 7.3 | 1.00* | 8 (14.3%) | 4 (12.5%) | 1.2 | 0.3 to 4.2 | 1.00* |

| rs1051660 Alt allele freq: 0.146 C > A OPRK1 | | | | | | | | | | | | | | | | | | | | |
|--|------------|------------|---------|------------|-------|-----------|------------|------|-------------|--------|------------|------------|---------|-------------|-------|-----------|------------|-----|-------------|-------|
| Allele | C/C | | C/A+A/A | | A/A | | C/C+C/A | | OR | 95% CI | P | G/G | G/A+A/A | | OR | 95% CI | P | A/A | G/G+G/A | |
| | n=60 | n=22 | n=22 | n=80 | n=2 | n=80 | n=40 | n=48 | | | | | n=11 | n=77 | | | | | | |
| Somnolence | 15 (25.0%) | 3 (13.6%) | 2.1 | 0.6 to 8.2 | .37* | 1 (50.0%) | 17 (21.3%) | 3.7 | 0.2 to 62.4 | .39* | 14 (35.0%) | 5 (10.4%) | 4.5 | 1.4 to 18.1 | .008* | 0 (0%) | 19 (24.7%) | 0 | 0 to 1.4 | .11* |
| Nausea | 10 (16.7%) | 4 (18.2%) | 0.9 | 0.3 to 3.2 | 1.00* | 1 (50.0%) | 13 (16.3%) | 5.2 | 0.3 to 87.8 | .31* | 8 (20.0%) | 6 (12.5%) | 1.8 | 0.6 to 5.6 | .39* | 0 (0%) | 14 (18.2%) | 0 | 0 to 2.4 | .36* |
| Constipation | 21 (35.0%) | 10 (45.5%) | 0.7 | 0.2 to 1.7 | .45* | 1 (50.0%) | 30 (37.5%) | 1.7 | 0.1 to 27.6 | 1.00* | 17 (42.5%) | 17 (35.4%) | 1.4 | 0.6 to 3.2 | .51* | 3 (27.3%) | 31 (40.3%) | 0.6 | 0.1 to 2.3 | .52* |
| Delirium | 7 (11.7%) | 3 (13.6%) | 0.8 | 0.2 to 3.6 | 1.00* | 0 (0.0%) | 10 (12.5%) | 0 | 0 to 39.7 | 1.00* | 3 (7.5%) | 7 (14.6%) | 0.5 | 0.1 to 2.0 | .34* | 2 (18.2%) | 8 (10.4%) | 1.9 | 0.4 to 10.5 | .61* |
| Urinary retention | 2 (3.3%) | 1 (4.5%) | 0.7 | 0.1 to 8.4 | 1.00* | 0 (0.0%) | 3 (3.8%) | 0 | 0 to 146.8 | 1.00* | 1 (2.5%) | 2 (4.2%) | 0.6 | 0.1 to 6.8 | 1.00* | 0 (0%) | 3 (3.9%) | 0 | 0 to 17.8 | 1.00* |
| Pruritus | 8 (13.3%) | 2 (9.1%) | 1.5 | 0.3 to 7.9 | .72* | 0 (0.0%) | 10 (12.5%) | 0 | 0 to 39.7 | 1.00* | 6 (15.0%) | 6 (12.5%) | 1.2 | 0.4 to 4.2 | .76* | 0 (0%) | 12 (15.6%) | 0 | 0 to 2.5 | 1.00* |

| rs6275 Alt allele freq: 0.352 A > G DRD2 | | | | | | | | | | | | | | | | | | | | |
|--|------------|------------|---------|------------|-------|-----------|------------|------|-------------|--------|------------|------------|------------|-------------|------|------------|------------|-----|-------------|-------|
| Allele | A/A | | A/G+G/G | | G/G | | A/A+A/G | | OR | 95% CI | P | A/A | A/G or G/G | | OR | 95% CI | P | G/G | A/A+A/G | |
| | n=40 | n=45 | n=45 | n=70 | n=15 | n=70 | n=23 | n=65 | | | | | n=29 | n=59 | | | | | | |
| Somnolence | 9 (22.5%) | 10 (22.2%) | 1.0 | 0.4 to 2.8 | 1.00* | 3 (20.0%) | 16 (22.9%) | 0.8 | 0.2 to 3.4 | 1.00* | 8 (34.8%) | 11 (16.9%) | 2.6 | 0.9 to 7.7 | .08* | 4 (13.8%) | 15 (25.4%) | 0.5 | 0.1 to 1.6 | .28* |
| Nausea | 8 (20.0%) | 5 (11.1%) | 2.0 | 0.6 to 6.7 | .37* | 1 (6.7%) | 12 (17.1%) | 0.4 | 0.04 to 2.9 | .45* | 4 (17.4%) | 10 (15.4%) | 1.2 | 0.3 to 4.1 | .75* | 4 (13.8%) | 10 (16.9%) | 0.8 | 0.2 to 2.8 | 1.00* |
| Constipation | 15 (37.5%) | 19 (42.2%) | 0.8 | 0.3 to 2.0 | .82* | 9 (60.0%) | 25 (35.7%) | 2.7 | 0.9 to 8.5 | .09* | 12 (52.2%) | 22 (33.8%) | 2.1 | 0.8 to 5.6 | .14* | 11 (37.9%) | 23 (39.0%) | 1.0 | 0.4 to 2.4 | 1.00* |
| Delirium | 6 (15.0%) | 4 (8.9%) | 1.8 | 0.5 to 6.9 | .51* | 1 (6.7%) | 9 (12.9%) | 0.5 | 0.1 to 4.1 | .68* | 1 (4.3%) | 9 (13.8%) | 0.3 | 0.03 to 2.4 | .44* | 5 (17.2%) | 5 (8.5%) | 2.3 | 0.6 to 8.5 | .29* |
| Urinary retention | 1 (2.5%) | 2 (4.4%) | 0.6 | 0.1 to 6.3 | 1.00* | 1 (6.7%) | 2 (2.9%) | 2.4 | 0.2 to 28.7 | .45* | 0 (0.0%) | 3 (4.6%) | 0 | 0 to 6.9 | .56* | 2 (6.9%) | 1 (1.7%) | 4.3 | 0.4 to 49.5 | .25* |
| Pruritus | 4 (10.0%) | 7 (15.6%) | 0.6 | 0.2 to 2.2 | .53* | 1 (6.7%) | 10 (14.3%) | 0.4 | 0.1 to 3.6 | .68* | 5 (21.7%) | 7 (10.8%) | 2.3 | 0.7 to 8.1 | .29* | 3 (10.3%) | 9 (15.3%) | 0.6 | 0.2 to 2.6 | .74* |

| rs2070995 Alt allele freq: 0.642 T > C GIRK2 | | | | | | | | | | | | | | | | | | | | |
|--|-----------|------------|---------|------------|-------|------------|------------|------|-------------|--------|------------|-----------|---------|------------|-------|-----------|------------|-----|-------------|-------|
| Allele | T/T | | C/C+C/T | | C/C | | C/A+A/A | | OR | 95% CI | P | A/A | C/A+A/A | | OR | 95% CI | P | A/A | C/C+C/A | |
| | n=10 | n=78 | n=78 | n=53 | n=35 | n=53 | n=67 | n=20 | | | | | n=83 | n=4 | | | | | n=83 | |
| Somnolence | 2 (20.0%) | 17 (21.8%) | 0.9 | 0.2 to 4.6 | 1.00* | 9 (25.7%) | 10 (18.9%) | 1.5 | 0.5 to 4.1 | .60* | 15 (22.4%) | 4 (20.0%) | 1.2 | 0.3 to 4.0 | 1.00* | 0 (0.0%) | 19 (22.9%) | 0 | 0 to 5.5 | .57* |
| Nausea | 2 (20.0%) | 12 (15.4%) | 1.4 | 0.3 to 7.3 | .66* | 7 (20.0%) | 7 (13.2%) | 1.6 | 0.5 to 5.2 | .55* | 11 (16.4%) | 3 (15.0%) | 1.1 | 0.3 to 4.5 | 1.00* | 1 (25.0%) | 13 (15.7%) | 1.8 | 0.2 to 18.6 | .51* |
| Constipation | 4 (40.0%) | 30 (38.5%) | 1.1 | 0.3 to 4.1 | 1.00* | 18 (51.4%) | 16 (30.2%) | 2.5 | 1.0 to 5.9 | .07* | 25 (37.3%) | 9 (45.0%) | 0.7 | 0.3 to 1.0 | .61* | 2 (50.0%) | 32 (38.6%) | 1.6 | 0.2 to 11.9 | .64* |
| Delirium | 1 (10.0%) | 9 (11.5%) | 0.9 | 0.1 to 7.5 | 1.00* | 4 (11.4%) | 6 (11.3%) | 1.0 | 0.3 to 3.9 | 1.00* | 6 (9.0%) | 4 (20.0%) | 0.4 | 0.1 to 1.6 | .23* | 0 (0.0%) | 10 (12.0%) | 0 | 0 to 12.5 | 1.00* |
| Urinary retention | 0 (0.0%) | 3 (3.8%) | 0 | 0 to 20.0 | 1.00* | 2 (5.7%) | 1 (1.9%) | 3.2 | 0.3 to 36.2 | .56* | 3 (4.5%) | 0 (0.0%) | ∞ | 0.1 to ∞ | 1.00* | 0 (0.0%) | 3 (3.6%) | 0 | 0 to 61.0 | 1.00* |
| Pruritus | 1 (10.0%) | 11 (14.1%) | 0.7 | 0.8 to 5.9 | 1.00* | 6 (17.1%) | 6 (11.3%) | 1.6 | 0.5 to 5.5 | .53* | 8 (11.9%) | 4 (20.0%) | 0.5 | 0.1 to 2.0 | .46* | 1 (25.0%) | 11 (13.3%) | 2.2 | 0.2 to 22.9 | .45* |

* Fisher's exact test
 ABCB1 = Adenosine Triphosphate Binding Cassette B1, CI = Confidence Interval, COMT = Catechol-O-Methyltransferase, DRD2 = Dopamine Receptor D2, FAAH = Fatty Acid Amide Hydrolase, GIRK2 = G-protein regulated Inward Rectifier potassium channel 2, OPRD1 = Opioid receptor 1, OPRK1 = Opioid κ Receptor 1, OPRM1 = Opioid μ Receptor 1, OR = Odds Ratio